nafamostat has been researched along with Infarction, Middle Cerebral Artery in 5 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, the effect of nafamostat mesilate (NM), a synthetic serine protease inhibitor, on BBB disruption following cerebral ischemia is unknown." | 7.83 | Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection. ( Chen, T; Fang, Y; Li, C; Liao, H; Pang, T; Shi, X; Wang, J; Zhang, L, 2016) |
| "NM treatment attenuated the brain infarct volume and the loss of body weight and improved the recovery of sensorimotor and cognitive functions." | 5.46 | Nafamostat Mesilate Improves Neurological Outcome and Axonal Regeneration after Stroke in Rats. ( Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Tao, X; Wang, J; Zhou, XF, 2017) |
| "After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points." | 5.43 | Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. ( Chen, T; Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Wang, J; Zhou, XF, 2016) |
| " However, the effect of nafamostat mesilate (NM), a synthetic serine protease inhibitor, on BBB disruption following cerebral ischemia is unknown." | 3.83 | Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection. ( Chen, T; Fang, Y; Li, C; Liao, H; Pang, T; Shi, X; Wang, J; Zhang, L, 2016) |
| "NM treatment attenuated the brain infarct volume and the loss of body weight and improved the recovery of sensorimotor and cognitive functions." | 1.46 | Nafamostat Mesilate Improves Neurological Outcome and Axonal Regeneration after Stroke in Rats. ( Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Tao, X; Wang, J; Zhou, XF, 2017) |
| "After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points." | 1.43 | Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats. ( Chen, T; Fang, Y; Li, C; Liao, H; Liu, Y; Sun, H; Wang, J; Zhou, XF, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, K | 1 |
| Shirasaka, T | 1 |
| Kano, H | 1 |
| Okita, Y | 1 |
| Kwon, SK | 1 |
| Ahn, M | 1 |
| Song, HJ | 1 |
| Kang, SK | 1 |
| Jung, SB | 1 |
| Harsha, N | 1 |
| Jee, S | 1 |
| Moon, JY | 1 |
| Suh, KS | 1 |
| Lee, SD | 1 |
| Jeon, BH | 1 |
| Kim, DW | 1 |
| Kim, CS | 1 |
| Wang, J | 3 |
| Li, C | 3 |
| Chen, T | 2 |
| Fang, Y | 3 |
| Shi, X | 1 |
| Pang, T | 1 |
| Zhang, L | 1 |
| Liao, H | 3 |
| Liu, Y | 2 |
| Sun, H | 2 |
| Zhou, XF | 2 |
| Tao, X | 1 |
5 other studies available for nafamostat and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Mitral valve repair in active infective endocarditis with cerebral infarction.
Topics: Anticoagulants; Benzamidines; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Diffusion Magneti | 2013 |
Nafamostat mesilate attenuates transient focal ischemia/reperfusion-induced brain injury via the inhibition of endoplasmic reticulum stress.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Benzamidines; Br | 2015 |
Nafamostat mesilate protects against acute cerebral ischemia via blood-brain barrier protection.
Topics: Animals; Astrocytes; Benzamidines; Blood-Brain Barrier; Brain Edema; Brain Ischemia; Endothelial Cel | 2016 |
Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats.
Topics: Animals; Behavior, Animal; Benzamidines; Disease Models, Animal; Guanidines; Infarction, Middle Cere | 2016 |
Nafamostat Mesilate Improves Neurological Outcome and Axonal Regeneration after Stroke in Rats.
Topics: Animals; Axons; Benzamidines; Body Weight; Brain Infarction; Cognition; Cyclic AMP Response Element- | 2017 |